Evidence map›Paper›PMID 40943522›Full record

ArticleInternational journal of molecular sciences2025

LAT1-Targeted Alpha Therapy Using

Haruna Takami, Yoshinori Imura, Hidetatsu Outani, Sho Nakai, Akitomo Inoue, Yuki Kotani, Seiji Okada, Kazuko Kaneda-Nakashima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Haruna TakamiDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Yoshinori ImuraDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0002-0430-5894
Hidetatsu OutaniDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0002-5407-5855
Sho NakaiDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Akitomo InoueDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.ORCID 0009-0007-3524-491X
Yuki KotaniDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0001-7157-4560
Seiji OkadaDepartment of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Kazuko Kaneda-NakashimaRadiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, Osaka 560-0043, Japan.ORCID 0000-0001-6657-5059

Funding

Japan Society for the Promotion of Science JP18K07323Japan Society for the Promotion of Science JP21K07619Japan Society for the Promotion of Science JP25K12504
6 · The paper itself

Abstract

Malignant bone and soft tissue tumors are often resistant to conventional treatment, and treatment options for unresectable and metastatic cases are limited. L-type amino acid transporter 1 (LAT1) is overexpressed in several malignancies, including sarcomas, making it an attractive target for targeted alpha therapy. In this study, we investigated the therapeutic efficacy of LAT1-targeted alpha therapy using a novel modified 3-astatin-211 Astato-α-methyl-L-tyrosine (

Indexed as

Alpha ParticlesBone NeoplasmsLarge Neutral Amino Acid-Transporter 1SarcomaAnimalsCell Line, TumorCell ProliferationCell SurvivalDNA DamageHumansMiceMice, NudeXenograft Model Antitumor AssaysLarge Neutral Amino Acid-Transporter 1SLC7A5 protein, humanAstatine-211L-type amino acid transporter 1osteosarcomasoft tissue sarcomatargeted alpha therapy

Identifiers

PMID40943522
PMCPMC12428879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.